History of or current hospitalization for COVID-19. <br/ > <br/ > For the current SARS-CoV-2 infection, any positive SARS-CoV-2 nucleic acid or antigen tests from any respiratory tract specimen (e.g., oropharyngeal, NP, or nasal swab, or saliva) collected Ë?240 hours prior to study entry. <br/ > <br/ > Current need for hospitalization or immediate medical attention in the clinical opinion of the site investigator. <br/ > <br/ > Use of any prohibited medication listed in section 5.4.1 and/or use of systemic or inhaled steroids for the purpose of COVID-19 treatment (new or increased dose from chronic baseline) within 30 days prior to study entry. <br/ > <br/ > Receipt of convalescent COVID-19 plasma or other antibody-based anti-SARS-CoV-2 treatment or prophylaxis at any time prior to study entry. <br/ > <br/ > Receipt of other available investigational treatments for SARS-CoV-2 at any time prior to study entry. This does not include drugs approved for other uses and taken for those uses. NOTE: <br/ > This does not include COVID-19 vaccines. <br/ > <br/ > Known allergy/sensitivity or any hypersensitivity to components of the investigational agent or placebo. See relevant appendix. <br/ > <br/ > Any co-morbidity requiring surgery within 7 days prior to study entry, or that is considered life threatening in the opinion of the site investigator within 30 days prior to study entry. <br/ > <br/ > Additional exclusion criteria as appropriate for the investigational agent. <br/ > <br/ > Currently pregnant <br/ > Currently breastfeeding <br/ >

History of or current hospitalization for COVID-19. <br/ > <br/ > For the current SARS-CoV-2 infection, any positive SARS-CoV-2 nucleic acid or antigen tests from any respiratory tract specimen (e.g., oropharyngeal, NP, or nasal swab, or saliva) collected Ë?240 hours prior to study entry. <br/ > <br/ > Current need for hospitalization or immediate medical attention in the clinical opinion of the site investigator. <br/ > <br/ > Use of any prohibited medication listed in section 5.4.1 and/or use of systemic or inhaled steroids for the purpose of COVID-19 treatment (new or increased dose from chronic baseline) within 30 days prior to study entry. <br/ > <br/ > Receipt of convalescent COVID-19 plasma or other antibody-based anti-SARS-CoV-2 treatment or prophylaxis at any time prior to study entry. <br/ > <br/ > Receipt of other available investigational treatments for SARS-CoV-2 at any time prior to study entry. This does not include drugs approved for other uses and taken for those uses. NOTE: <br/ > This does not include COVID-19 vaccines. <br/ > <br/ > Known allergy/sensitivity or any hypersensitivity to components of the investigational agent or placebo. See relevant appendix. <br/ > <br/ > Any co-morbidity requiring surgery within 7 days prior to study entry, or that is considered life threatening in the opinion of the site investigator within 30 days prior to study entry. <br/ > <br/ > Additional exclusion criteria as appropriate for the investigational agent. <br/ > <br/ > Currently pregnant <br/ > Currently breastfeeding <br/ >